VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) Director Patrick G. Lepore acquired 13,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was bought at an average price of $3.91 per share, with a total value of $50,830.00. Following the purchase, the director now directly owns 36,472 shares in the company, valued at approximately $142,605.52. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
VYNE Therapeutics Stock Performance
Shares of VYNE opened at $3.91 on Monday. The stock has a 50-day simple moving average of $3.32 and a 200-day simple moving average of $4.55. The stock has a market capitalization of $54.57 million, a PE ratio of -0.38 and a beta of 1.42. VYNE Therapeutics Inc. has a 1 year low of $1.99 and a 1 year high of $8.73.
Analyst Upgrades and Downgrades
Separately, HC Wainwright decreased their price objective on VYNE Therapeutics from $28.00 to $5.75 and set a “buy” rating for the company in a research note on Monday, October 30th.
Institutional Investors Weigh In On VYNE Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its holdings in VYNE Therapeutics by 41.0% in the second quarter. Renaissance Technologies LLC now owns 36,076 shares of the company’s stock valued at $148,000 after purchasing an additional 10,495 shares in the last quarter. Susquehanna International Group LLP boosted its holdings in VYNE Therapeutics by 9.3% in the first quarter. Susquehanna International Group LLP now owns 18,012 shares of the company’s stock valued at $55,000 after purchasing an additional 1,528 shares in the last quarter. HRT Financial LP acquired a new position in VYNE Therapeutics in the first quarter valued at approximately $31,000. Millennium Management LLC boosted its holdings in VYNE Therapeutics by 145.6% in the fourth quarter. Millennium Management LLC now owns 488,012 shares of the company’s stock valued at $73,000 after purchasing an additional 289,298 shares in the last quarter. Finally, Cetera Advisor Networks LLC acquired a new position in VYNE Therapeutics in the second quarter valued at approximately $45,000. Institutional investors and hedge funds own 12.15% of the company’s stock.
VYNE Therapeutics Company Profile
VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
- Five stocks we like better than VYNE Therapeutics
- How to Invest in Small Cap Stocks
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Invest in the Healthcare Sector
- MarketBeat Week in Review – 11/13 – 11/17
- What Are Utility Stocks? An Overview of the Utilities Sector
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.